Enzo Biochem (ENZ) (~$65MM market cap) in July 2023, closed on the sale of their medical laboratory division to Labcorp (LH) leaving their subscale however rising Enzo Life Sciences (“ELS”) division and a slug of money on the RemainCo. Rhyming with different related setups (most not too long ago PFSW), the corporate is probably going dressing up the ELS division on the market to finish the two-step liquidation of the corporate. The ELS section makes merchandise (picks and shovels for biotechs) for drug growth and medical analysis, it does about $32MM in gross sales yearly making it an after-thought within the massive however mid-to-high single digit rising business. At the moment ELS is roughly breakeven earlier than company overhead, whereas that ought to enhance, after company overhead, ENZ as an entire, is burning money and has little cause to exist.
Comparables of comparable measurement (most are worthwhile mid-large caps) are a bit exhausting to come back by for the ELS section (there could be apparent ones that I am lacking, in that case, please level them out within the feedback), however they do personal the actual property for the enterprise (about 56,000 sq. ft of producing/analysis house in Farmingdale, NY), simply throwing a primary 1x TTM income a number of on the ELS enterprise itself and including the PPE, will get me a couple of worth of $45MM for the remaining enterprise. Including within the present NCAV and accounting for additional money burn, I get a proforma worth of roughly $1.75/share.
In a bullish situation, perhaps they’ll get upward of 2x income for the ELS section and it could possibly be a close to double from present costs. This is not a singular thought, however as I’ve stated earlier than, I believe traders are typically impatient with these setups, it takes longer than traders would suppose to unwind the operations of segments that on the floor look separate. As we come up on the primary anniversary of the medical labs sale, a second asset sale within the subsequent quarter or two is a extra affordable timeline.
Different random ideas:
- Enzo’s former medical laboratory section was topic to a ransomware assault final Could previous to the shut of their cope with Labcorp, numerous delicate info was stolen together with a number of hundred thousand social safety numbers. Enzo is going through some lawsuits, however hasn’t supplied any estimated legal responsibility at this level.
- Enzo stopped doing earnings calls after the asset sale announcement, they have not returned to conducting earnings calls, pointing to their present construction not being the long run mannequin going ahead.
- Steven Pully is the brand new Chairman of the Board, he is a companion/co-founder of Speyside Companions, an advisory store that focuses on companies in transition, he is served on 29 boards, together with a number of that ended up pseudo liquidating, just like ENZ’s presumed path.
- What is the “ADES threat” right here? Mentioned in any other case, what is the threat the corporate will likely be a purchaser relatively than a vendor? I believe that is unlikely for the reason that board and shareholder registry is stuffed with worth and activist traders who’ve proven up within the final two years, aren’t emotionally tied to the enterprise like a former founder or CEO.
- Bradley Radoff, a personal investor, owns 8+% of the inventory and is on the board of administrators.
- CEO Kara Cannon was beforehand the COO, after the previous CEO stepped down 9/6 she took on the interim CEO title that was later graduated to the everlasting CEO. Her contract pays her a 0.75% Transaction Bonus on the any sale incentivizing her to go together with the two-step liquidation technique.
Disclosure: I personal shares of ENZ
